 Home > Active Ingredient News > Study of Nervous System > Mov Disord: Neurofilament light chain can predict the disease severity and progression of multiple system atrophy

Mov Disord: Neurofilament light chain can predict the disease severity and progression of multiple system atrophy

 Last Update: 2021-11-13
 Source: Internet
 Author: User

Tags

properties plasma

test lyme disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Multiple system atrophy (MSA) is a rare adult-onset progressive neurodegenerative disease characterized by a variable combination of autonomic failure, Parkinson's disease, cerebellar ataxia, and pyramidal signs
.

MSA progresses rapidly and there is no effective treatment; the median survival time is about 6 to 10 years

West China Hospital Huifang Shang et al.
published a research article in Mov Disord.
They detected plasma NFL levels in MSA patients to study whether plasma NFL levels are related to the severity of MSA, and to clarify the relationship between plasma NFL and MSA progression, and to explore whether plasma NFL levels It is related to the progression of motor and cognitive function in MSA patients
.

A total of 91 MSA patients and 60 healthy controls (HCs) were included
.

The plasma NFL level of MSA patients was significantly higher than that of HCs at baseline (P<0.

The plasma NFL level of MSA patients was significantly higher than HCs at baseline (P<0.

Plasma neurofilament light chain (NFL) levels in different groups and their correlation with disease severity
.

(A) Comparison of plasma NFL levels between patients with multiple system atrophy (MSA) and healthy controls (HCs), and comparison of plasma NFL levels between baseline examination and 1-year follow-up of 64 MSA patients

Plasma neurofilament light chain (NFL) levels in different groups and their correlation with disease severity

The baseline NFL level was significantly correlated with the UMSARS-II score of MSA patients (P<0.

In summary, the baseline plasma NFL level was significantly correlated with the severity and progression of exercise in MSA patients (P<0.

Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy [published online ahead of print, 2021 Oct 31].

Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy [published online ahead of print, 2021 Oct 31].
Mov Disord.
2021;10.
1002/mds.
28847.
doi:10.
1002/mds.
28847 Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy [published online ahead of print, 2021 Oct 31] Mov Disord 2021; 10.
1002 / mds.
28847 doi:.
.
10.
1002 / mds.
28847.
in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.